Document is current

Article History

Received: 5 November 2024

Accepted: 14 March 2025

First Online: 24 March 2025

Declarations

:

: The study was approved by the institutional review board of Hospital La Princesa, Madrid, on 3 November 2020 (Royal Decree 957/2020), which served as central reference ethics committee. The study was compliant with all legal and regulatory requirements, the International Conference on Harmonisation Good Clinical Practice E6 guidelines and the Declaration of Helsinki.

: In accordance with Spanish regulations, patient consent was waived due to the retrospective design of the study as patients completed their treatment prior to study initiation; therefore, the study represented no harm for the participants.

: Not applicable.

: Julian Torre-Cisneros has received educational grants and fee for advisory activities from Shionogi, Pfizer, MSD, Menarini; and unrestricted research grants from Pfizer and MSD. Alex Soriano has received honoraria for lectures and advisory boards from Shionogi, Pfizer, Menarini, Angelini, Advance Pharma and Gilead, and grants from Pfizer and Gilead. Ricard Ferrer has received honoraria for lectures from Gilead, Menarini, MSD, Shionogi, and ThermoFisher; consulting fees from Cytosorbent, Inoterm, and Pfizer; and holds stocks or stock options from Grifols. Carmen De La Fuente Martos received honoraria from Shionogi & Co., Ltd., Osaka, Japan, for participation in this study. Jessica Sarda, A. Javier Gonzalez Calvo, Stefano Verardi, Andreas Karas are employees of Shionogi.